港股異動 | 藥明生物(2269.HK)跌4.62% 大股東再度減持
格隆匯4月27日丨藥明生物(2269.HK)低開,現跌4.62%,報109.5港元,成交達125億港元,總市值4615億港元。藥明生物公佈,大股東WuXi Biologics Holdings Ltd(WBH),配售1.08億股現有股份,佔已發行股本約2.56%,配售價為107港元,較昨日收市價114.8港元折讓6.79%,套現115.56億港元。配售完成後,WBH持股由約20%減少至約17.44%;且將繼續為公司主要股東。藥明生物的主要股東WBH經常配售舊股,單計去年便先後減持4次。最近一次為今年1月初,配售逾1億股,相當於已發行股本2.5%,套現超過98億港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.